Checking in with Sanofi’s Diabetes and Cardiovascular Business in 3Q17
Diabetes and cardiovascular franchise
Sanofi’s (SNY) diabetes and cardiovascular franchises include the blockbuster diabetes drug Lantus, which contributes over 70% of total revenues for diabetes products. For 3Q17, these franchises’ combined revenues fell 9.1% at constant exchange rates to 1.67 billion euros, including sales from emerging markets.
Interested in SNY? Don't miss the next report.
Receive e-mail alerts for new research on SNY
After excluding the revenues for emerging markets, the diabetes and cardiovascular franchises reported revenues of 1.30 billion euros for 3Q17—a 14.8% YoY (year-over-year) fall.
The diabetes franchise reported revenues of 1.55 billion euros in 3Q17—a 10% YoY fall, including revenues from emerging markets. After excluding the revenues from emerging markets, the franchise reported revenues of 1.18 billion euros for 3Q17, or 16.3% lower YoY.
Lantus, the blockbuster drug in the diabetes franchise, reported revenues of 867 million euros in 3Q17, or 22% lower YoY, excluding revenues from emerging markets. US sales for Lantus fell 25.4% YoY to 608 million euros, while European sales fell 14% YoY to 184 million euros in 3Q17.
Toujeo, another drug from the diabetes franchise, reported a 14% YoY rise at constant exchange rates to 179 million euros, excluding revenues from emerging markets. This growth in revenues was driven by increased sales across all international markets, excluding US markets, which reported a 6.6% fall in US sales.
Multaq and Praluent—two drugs from Sanofi’s cardiovascular franchise—reported a combined 4% YoY rise in revenues at constant exchange rates to 123 million euros in 3Q17, including the revenues from emerging markets. Multaq sales fell to 80 million euros, excluding emerging markets—a 4.6% fall—driven by lower US sales. Praluent revenues rose 26.5% YoY at constant exchange rates to 41 million euros, excluding emerging markets.
Notably, the BLDRS Europe Select ADR ETF (ADRU) has 22.3% of its total investments in the healthcare sector, with 6.3% in Novartis AG ADR (NVS), 3.0% in Sanofi ADR (SNY), 2.5% in GlaxoSmithKline ADR (GSK), and 2.4% in AstraZeneca ADR (AZN).